This title appears in the Scientific Report :
2023
Please use the identifier:
http://dx.doi.org/10.1093/neuonc/noac229 in citations.
Please use the identifier: http://hdl.handle.net/2128/34417 in citations.
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET
BackgroundWe evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy.MethodsThirty-six adult patients with WHO CNS grade 3 or 4 gliomas (glioblastoma, 69%) at recurrence (median number of recur...
Saved in:
Personal Name(s): | Wollring, Michael M |
---|---|
Werner, Jan-Michael / Bauer, Elena K / Tscherpel, Caroline / Ceccon, Garry S / Lohmann, Philipp / Stoffels, Gabriele / Langen, Karl-Josef / Kabbasch, Christoph / Goldbrunner, Roland / Fink, Gereon R / Galldiks, Norbert (Corresponding author) | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 Physik der Medizinischen Bildgebung; INM-4 |
Published in: | Neuro-Oncology, 25 (2023) 5, S. 984–994 |
Imprint: |
Oxford
Oxford Univ. Press
2023
|
DOI: |
10.1093/neuonc/noac229 |
Document Type: |
Journal Article |
Research Program: |
Brain Dysfunction and Plasticity Multilevel Brain Organization and Variability Neuroimaging |
Link: |
Get full text Published on 2022-10-10. Available in OpenAccess from 2023-10-10. |
Publikationsportal JuSER |
Please use the identifier: http://hdl.handle.net/2128/34417 in citations.
BackgroundWe evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy.MethodsThirty-six adult patients with WHO CNS grade 3 or 4 gliomas (glioblastoma, 69%) at recurrence (median number of recurrences, 1; range, 1–3) were retrospectively identified. Besides MRI, serial FET PET scans were performed at baseline and early after chemotherapy initiation (not later than two cycles). Tumor-to-brain ratios (TBR), metabolic tumor volumes (MTV), the occurrence of new distant hotspots with a mean TBR >1.6 at follow-up, and the dynamic parameter time-to-peak were derived from all FET PET scans. PET parameter thresholds were defined using ROC analyses to predict PFS of ≥6 months and OS of ≥12 months. MRI response assessment was based on RANO criteria. The predictive values of FET PET parameters and RANO criteria were subsequently evaluated using univariate and multivariate survival estimates.ResultsAfter treatment initiation, the median follow-up time was 11 months (range, 3–71 months). Relative changes of TBR, MTV, and RANO criteria predicted a significantly longer PFS (all P ≤ .002) and OS (all P ≤ .045). At follow-up, the occurrence of new distant hotspots (n ≥ 1) predicted a worse outcome, with significantly shorter PFS (P = .005) and OS (P < .001). Time-to-peak changes did not predict a significantly longer survival. Multivariate survival analyses revealed that new distant hotspots at follow-up FET PET were most potent in predicting non-response (P < .001; HR, 8.578).ConclusionsData suggest that FET PET provides complementary information to RANO criteria for response evaluation of lomustine-based chemotherapy early after treatment initiation. |